Boundless Bio

Boundless Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive. Our Culture: At Boundless, you’ll experience what it means to be out in front of the wave. Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers. Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless. We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success. At Boundless, we’re all in. We are unbound by convention, bound to save lives. Career Inquiries careers@boundlessbio.com General Information Inquiries info@boundlessbio.com

Company Details

Employees
65
Address
10955 Alexandria Way,
Phone
858-766-9912
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
events.
HQ
San Diego, CA
Looking for a particular Boundless Bio employee's phone or email?

Boundless Bio Questions

News

Boundless Bio to Present Research on Novel Cancer Therapeutics at AACR-NCI-EORTC Conference 2025 - Quiver Quantitative

Boundless Bio to Present Research on Novel Cancer Therapeutics at AACR-NCI-EORTC Conference 2025 Quiver Quantitative

Oct 23 Poster: BBI-825 + BBI-355 synergy — Boundless Bio at AACR-NCI-EORTC 2025 in Boston - Stock Titan

Oct 23 Poster: BBI-825 + BBI-355 synergy — Boundless Bio at AACR-NCI-EORTC 2025 in Boston Stock Titan

Boundless Bio Announces Portfolio Prioritization and Extended Operating Runway Through 2028 with Focus on Novel Combination Therapy and New Development Candidate - Nasdaq

Boundless Bio Announces Portfolio Prioritization and Extended Operating Runway Through 2028 with Focus on Novel Combination Therapy and New Development Candidate Nasdaq

Boundless Bio lays off 33% of staff as lead program stumbles - Fierce Biotech

Boundless Bio lays off 33% of staff as lead program stumbles Fierce Biotech

Boundless Bio reports R&D pipeline progress - The Pharma Letter

Boundless Bio reports R&D pipeline progress The Pharma Letter

Boundless Bio (BOLD) Q2 R&D Drops 17% - Nasdaq

Boundless Bio (BOLD) Q2 R&D Drops 17% Nasdaq

Boundless Bio drops clinical-stage cancer drug over phase 1 data, shakes up C-suite - Fierce Biotech

Boundless Bio drops clinical-stage cancer drug over phase 1 data, shakes up C-suite Fierce Biotech

Boundless Bio Announces Pricing of Initial Public Offering - The AI Journal

Boundless Bio Announces Pricing of Initial Public Offering The AI Journal

Wilson Sonsini Advises Boundless Bio on IP Matters Related to IPO - Wilson Sonsini

Wilson Sonsini Advises Boundless Bio on IP Matters Related to IPO Wilson Sonsini

Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby on The Long Run - Timmerman Report

Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby on The Long Run Timmerman Report

Boundless Bio Appoints Klaus Wagner, M.D., Ph.D., as Chief Medical Officer - Business Wire

Boundless Bio Appoints Klaus Wagner, M.D., Ph.D., as Chief Medical Officer Business Wire

Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation - Yahoo Finance

Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation Yahoo Finance

Boundless Bio doses first subject in advanced cancer treatment trial - Clinical Trials Arena

Boundless Bio doses first subject in advanced cancer treatment trial Clinical Trials Arena

Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO - BioPharma Dive

Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO BioPharma Dive

Boundless Bio tests a cancer drug targeting once-mysterious DNA loops - statnews.com

Boundless Bio tests a cancer drug targeting once-mysterious DNA loops statnews.com

Boundless Bio Launches $100M IPO to Advance Cancer Therapy Candidates - BioSpace

Boundless Bio Launches $100M IPO to Advance Cancer Therapy Candidates BioSpace

Boundless Bio breaks IPO lull with $100M fundraise - BioPharma Dive

Boundless Bio breaks IPO lull with $100M fundraise BioPharma Dive

Boundless Bio Announces ‘Modest Reduction’ to San Diego Workforce - BioSpace

Boundless Bio Announces ‘Modest Reduction’ to San Diego Workforce BioSpace

Boundless Bio drug shrinks tumors in mice by targeting extrachromosomal DNA - Fierce Biotech

Boundless Bio drug shrinks tumors in mice by targeting extrachromosomal DNA Fierce Biotech

Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO - Fierce Biotech

Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO Fierce Biotech

Boundless Bio collaborates with Lilly for Phase I/II solid tumour trial - Clinical Trials Arena

Boundless Bio collaborates with Lilly for Phase I/II solid tumour trial Clinical Trials Arena

Boundless Bio boldly goes public with $100M IPO - Fierce Biotech

Boundless Bio boldly goes public with $100M IPO Fierce Biotech

Bayer-Backed Drug Maker Boundless Bio Raises $100 Million in IPO - Bloomberg

Bayer-Backed Drug Maker Boundless Bio Raises $100 Million in IPO Bloomberg

Boundless Bio - The Pharma Letter

Boundless Bio The Pharma Letter

Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug - MedCity News

Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug MedCity News

Startup Boundless Bio files to go public – San Diego’s first life science IPO of 2024 - San Diego Union-Tribune

Startup Boundless Bio files to go public – San Diego’s first life science IPO of 2024 San Diego Union-Tribune

Boundless Bio corrals $105M financing round to prep aggressive cancer programs for clinic - Fierce Biotech

Boundless Bio corrals $105M financing round to prep aggressive cancer programs for clinic Fierce Biotech

Boundless Bio: Precision Oncology Company Secures $100 Million In Oversubscribed Series C Funding Round - Pulse 2.0

Boundless Bio: Precision Oncology Company Secures $100 Million In Oversubscribed Series C Funding Round Pulse 2.0

Boundless Bio uncloaks with $46M to create new cancer drugs aimed at extrachromosomal DNA - Fierce Biotech

Boundless Bio uncloaks with $46M to create new cancer drugs aimed at extrachromosomal DNA Fierce Biotech

BOLD Stock Price and Chart — NASDAQ:BOLD - TradingView

BOLD Stock Price and Chart — NASDAQ:BOLD TradingView

Top Boundless Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant